Actinium Pharmaceuticals Inc (ATNM)

[GoodGuyBill]

Actinium Presents Positive Findings from Mid-Point Analysis of Pivotal SIERRA Trial of Iomab-B at 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (TCT)

https://finance.yahoo.com/news/actinium-presents-positive-findings-mid-123000211.html

- Substantially lower rates of febrile neutropenia and sepsis in patients receiving Iomab-B compared to patients receiving salvage chemotherapy in the control arm

- 78 percent of patients in the Iomab-B arm are potentially evaluable for the primary endpoint compared to 13 percent in the control arm after factoring in 100-day non-relapse transplant related mortality

- Key protocol amendment allowing patients failing venetoclax induction therapy to enroll in the SIERRA trial is expected to increase eligible patient pool